20 November 2023
20 November 2023
Vitrakvi is intended for treating NTRK gene fusion-positive solid tumours.
The new business will offer digital technology solutions to cut down time and expenditure for new drug development.
As part of the UK Government and NHS’s primary care access recovery plan, the service aims to enhance healthcare accessibility.
Following the agreement, ABVC will hold 57% of the consolidated shares of AiBtl.
In a Phase II trial, the Brukinsa combination regimen offered an ORR of 69% versus 45.8% in the obinutuzumab arm.
Apollomics’ Chinese partner, Avistone Biotechnology, received a conditional approval for Velbretinib from China's NMPA.
The project under Professor Gail Risbridger is one of ten developments to share $50m in NHMRC funding.
The pivotal Phase II trial is designed to evaluate Vigil in platinum-sensitive recurrent ovarian cancer patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.
Give your business an edge with our leading industry insights.
